Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Travere Therapeutics, Inc. (TVTX : NSDQ)

• Company Description    Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. Travere Therapeutics Inc., formerly known as Retrophin Inc., is based in SAN DIEGO. Number of Employees: 497

• Price / Volume Information    Yesterday's Closing Price: $44.43 Daily Weekly Monthly 20 Day Moving Average: 2,421,172 shares Shares Outstanding: 92.99 (millions) Market Capitalization: $4,131.68 (millions) Beta: 1.13 52 Week High: $48.61 52 Week Low: $13.88 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 8.84% 3.53% 12 Week 49.49% 38.20% Year To Date 16.28% 7.65%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3611 VALLEY CENTRE DR SUITE 300 - SAN DIEGO,CA 92130 USA ph: 888-969-7879 fax: 302-645-1280 ir@travere.com http://www.travere.com

• General Corporate Information    Officers Eric Dube - Chief Executive Officer Gary Lyons - Chairman Christopher Cline - Chief Financial Officer Sandra Calvin - Senior Vice President and Chief Accounting Officer Roy D. Baynes - Director Peer Information Travere Therapeutics, Inc. (CORR.) Travere Therapeutics, Inc. (RSPI) Travere Therapeutics, Inc. (CGXP) Travere Therapeutics, Inc. (BGEN) Travere Therapeutics, Inc. (GTBP) Travere Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 89422G107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/05/26 Share - Related Items Shares Outstanding: 92.99 Most Recent Split Date: (:1) Beta: 1.13 Market Capitalization: $4,131.68 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.14 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.26 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 41.85 Price/Cash Flow: 122.69 Price / Sales: 7.71 EPS Growth vs. Year Ago Period: 17.02% vs. Previous Quarter: -1,400.00% Sales Growth vs. Year Ago Period: 55.63% vs. Previous Quarter: -1.92% ROE 03/31/26 - -26.16 12/31/25 - -40.24 09/30/25 - -178.68 ROA 03/31/26 - -3.71 12/31/25 - -4.55 09/30/25 - -15.83 Current Ratio 03/31/26 - 3.13 12/31/25 - 2.74 09/30/25 - 2.75 Quick Ratio 03/31/26 - 3.08 12/31/25 - 2.70 09/30/25 - 2.71 Operating Margin 03/31/26 - -3.90 12/31/25 - -5.21 09/30/25 - -20.32 Net Margin 03/31/26 - -4.00 12/31/25 - -5.21 09/30/25 - -20.32 Pre-Tax Margin 03/31/26 - -8.36 12/31/25 - -10.04 09/30/25 - -20.32 Book Value 03/31/26 - 1.06 12/31/25 - 1.28 09/30/25 - 0.82 Inventory Turnover 03/31/26 - 1.39 12/31/25 - 2.13 09/30/25 - 2.09 Debt-to-Equity 03/31/26 - 3.16 12/31/25 - 2.71 09/30/25 - 4.23 Debt-to-Capital 03/31/26 - 75.97 12/31/25 - 73.08 09/30/25 - 80.89

Powered by Zacks Investment Research ©